Immune Response BioPharma Announces REMUNE Granted Orphan Designation for Pediatric HIV/AIDS

February 18, 2014 Immune Response BioPharma, Inc. Today, Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS diseases by the FDA. The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Orphan Drug …

#Vaccine #Pricing: An analytic perspective by Sheldon Jacobson

At this year's World Vaccine Congress Washington Prof Sheldon Jacobson, Professor and Director for the Simulation & Optimization Laboratory at the University of Illinois at Urbana-Champaign (UIUC), shared with us his research and views on vaccine pricing. Prof Jacobson talked us through the vaccine pricing challenges the industry is facing, notably mentioning the key issues related to: Corporate Profits versus …

Universal Immunization Programme in India: Challenges and Opportunities

At the 12th annual World Vaccine Congress we will have the pleasure to welcome Mrs Anuradha Gupta, the Joint Secretary for Reproductive and Child Health for the Indian Ministry of Health and Welfare.   Mrs Gupta will discuss the existing vaccine recommendations, coverage rates and promising future indications. What are the opportunities and threats from a vaccine maker’s perspective?   …

#Takeda’s new #vaccine development unit headed by Dr Rajeev Venkayya

It was announced shortly before the holidays that Dr. Rajeev Venkayya, the director of vaccine delivery in the Global Health Program at the Bill & Melinda Gates Foundation, will be heading up the new vaccine development unit at Takeda as of January this year.   Takeda will aim to focus their efforts towards expanding into pediatric vaccines on top of …